If You Invested in TFA THERAPEUTICS INC (RAJAF)

Cordyceps Sunshine Biotech Holdings Co., Ltd. (traded under the symbol RAJAF) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934. According to its SEC filings, the company prepares consolidated financial statements and files reports as a foreign issuer on Form 20-F and Form 6-K. The available disclosure highlights its corporate governance processes and its engagement with independent registered public accounting firms.

The company has disclosed that it maintains consolidated balance sheets and consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit), and cash flows for its fiscal years. These filings indicate that Cordyceps Sunshine Biotech Holdings Co., Ltd. follows formal reporting standards and works with external auditors to review its financial information. As a foreign issuer, it uses the Form 6-K mechanism to inform investors of significant corporate events.

Auditor relationships and corporate oversight

In a current report on Form 6-K, Cordyceps Sunshine Biotech Holdings Co., Ltd. described a change in its independent registered public accounting firm. The filing explains that the company terminated its prior auditor and appointed a new firm to audit its financial statements. The report notes that the decision to change auditors was approved and ratified by the company’s Board of Directors, underscoring the role of board-level oversight in its financial reporting processes.

The filing further states that the prior auditor’s reports on the company’s consolidated financial statements for the referenced fiscal years did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. The company also reported that there were no disagreements with the prior auditor on accounting principles, financial statement disclosure, or auditing scope or procedure, and that there were no reportable events as described in the SEC’s Regulation S-K.

Use of Form 6-K and communication with regulators

As a foreign private issuer, Cordyceps Sunshine Biotech Holdings Co., Ltd. uses Form 6-K to provide information about material events, including changes in its certifying accountant. In the referenced report, the company states that it provided its former auditor with a copy of the disclosure and requested a letter addressed to the SEC indicating whether the auditor agreed with the company’s statements. That letter is included as an exhibit to the Form 6-K, reflecting the company’s process for documenting auditor transitions.

The company also discloses that, prior to engaging its new independent registered public accounting firm, neither it nor anyone acting on its behalf consulted the new firm on the application of accounting principles to specific transactions or on the type of audit opinion that might be rendered on its consolidated financial statements. The filing states that there were no matters that were the subject of a disagreement or reportable event with respect to the new firm, consistent with SEC disclosure requirements for auditor changes.

Regulatory reporting framework

Cordyceps Sunshine Biotech Holdings Co., Ltd. indicates in its filing that it files annual reports on Form 20-F. This form is used by foreign private issuers to provide audited annual financial statements and related disclosures. The reference to consolidated balance sheets and other consolidated financial statements suggests that the company reports on a group basis, covering the parent company and its subsidiaries.

Through its SEC reports, the company provides information that allows investors and analysts to review its financial reporting practices, auditor relationships, and governance processes related to financial disclosure. While the available filing focuses on the change of independent registered public accounting firm, it also confirms that the company’s financial statements for the referenced years were audited without adverse or disclaimed opinions.

Business information limitations

The SEC filing excerpt centers on auditor changes and does not provide detailed information about the company’s specific industry, operating segments, products, or geographic markets beyond its identification as a foreign issuer. As a result, only limited business description details can be drawn directly from the available data. Investors researching RAJAF may wish to review the company’s full Form 20-F and additional Form 6-K reports for more comprehensive information on its operations and strategy.